Press Release

BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO BLOOMBERG: LPC IN

Lupin announces favorable ruling for generic Yaz® Oral Contraceptive Tablets

Mumbai, Baltimore, April 17, 2013: Pharma Major, Lupin Ltd. announced today that the U.S Court of Appeals for the Federal Circuit has ruled in its favor regarding its appeal of a previous judgment by a lower court for Bayer AG's Yaz® oral contraceptive product.

On April 16, 2013 the United States Court of Appeals for the Federal Circuit has ruled that United States Patent No. RE 37,564 (the RE '564 Patent) is invalid thereby reversing the district court's decision of validity.

Confirming the same a Lupin Spokesperson stated; "We are pleased with the ruling which paves the path for entry of generic product which would immensely benefit customers". Lupin is currently seeking approval from the US FDA for its generic and is working out its commercialization plan.

Lupin's Generic Drospirenone and Ethinyl Estradiol Tablets (3 mg + 0.02 mg) of Bayer AG's Yaz® tablets are indicated for prevention of pregnancy, to treat the symptoms of premenstrual dysphoric disorder (PMDD) for women and to treat moderate acne for women at least 14 years old only if the patient desires an oral contraceptive for birth control. The total sales for Branded and generic sales for the product stood at USD 361 million (IMS MAT Dec 2012).

About Lupin Limited

Headquartered in Mumbai, Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.

Lupin is the 5th largest and fastest growing generics player in the US (5.1% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales. The Company is also the fastest growing top 10 generic pharmaceutical players in Japan and South Africa (IMS).

For the financial year ended March 2012, Lupin's Consolidated Total Income and Profit after Tax were Rs. 70,972 million (USD 1.49 billion) and Rs.8,676 million (USD 182 million) respectively. Please visit http://www.lupinworld.com for more information.

Lupin Pharmaceuticals, Inc. is the wholly owned U.S. subsidiary of Lupin Limited. Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is dedicated to delivering high-quality, affordable generic medicines and branded formulations trusted by healthcare professionals and patients across geographies. For more information, visit http://www.lupinpharmaceuticals.com

For further information or queries please contact -
Shamsher Gorawara
Head – Corporate Communications
Lupin Limited
Ph: +91 98 20 338 555
Email: shamshergorawara@lupinpharma.com

or

Press Release

BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO BLOOMBERG: LPC IN

Rajiv Pillai
Head – Investor Relations
Lupin Limited
Ph: +91 98 20 552 083
Email: rajivpillai@lupinpharma.com

Safe Harbor Statement

Yaz® is a registered trademark of Bayer Schering Pharma Aktiengesellschaft.